Vitamin D deficiency in type 1 narcolepsy: a reappraisal

Sleep Medicine

Volumn 29, Issue , 2017, Pages 1-6

  Dauvilliers, Yves ^a,b   Evangelista, Elisa ^a   Lopez, Regis ^a,b   Barateau, Lucie ^a,b   Scholz, Sabine ^a   Crastes de Paulet, Barbara ^c   Carlander, Bertrand ^a   Jaussent, Isabelle ^b  

^a GUI DE CHAULIAC HOSPITAL   (France)

^b INSERM U1061   (France)

^c LAPEYRONIE HOSPITAL   (France)

Author keywords

Autoimmunity; Hypocretin orexin; Narcolepsy; Sleepiness; Vaccination; Vitamin D

Indexed keywords

25 HYDROXYERGOCALCIFEROL; 25 HYDROXYVITAMIN D; COLECALCIFEROL; INFLUENZA VACCINE; 25-HYDROXYVITAMIN D; VITAMIN D;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; CASE CONTROL STUDY; CAUCASIAN; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE SEVERITY; EPWORTH SLEEPINESS SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NARCOLEPSY; NARCOLEPSY TYPE 1; OBESITY; PRESCHOOL CHILD; PRIORITY JOURNAL; SEASONAL VARIATION; SEX DIFFERENCE; VACCINATION; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; AGE; ANALOGS AND DERIVATIVES; BLOOD; COMPLICATION; SEASON;

ADULT; AGE FACTORS; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; NARCOLEPSY; SEASONS; SEX FACTORS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 85002995635     PISSN: 13899457     EISSN: 18785506     Source Type: Journal    
DOI: 10.1016/j.sleep.2016.05.008     Document Type: Article

References (39)

1. [1] Dauvilliers, Y., Arnulf, I., Mignot, E., Narcolepsy with cataplexy. Lancet 369 (2007), 499–511.
2. [2] Dauvilliers, Y., Montplaisir, J., Molinari, N., et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology 57 (2001), 2029–2033.
3. [3] Mignot, E., Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet 68 (2001), 686–699.
4. [4] Ollila, H.M., Ravel, J.-M., Han, F., et al. HLA-DPB1 and HLA class I confer risk of and protection from narcolepsy. Am J Hum Genet 96 (2015), 136–146.
5. [5] Hallmayer, J., Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet 41 (2009), 708–711.
6. [6] Kornum, B.R., Kawashima, M., Faraco, J., et al. Common variants in P2RY11 are associated with narcolepsy. Nat Genet 43 (2011), 66–71.
7. [7] Aran, A., Lin, L., Nevsimalova, S., et al. Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep 32 (2009), 979–983.
8. [8] Han, F., Lin, L., Warby, S.C., et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol 70 (2011), 410–417.
9. [9] Nohynek, H., Jokinen, J., Partinen, M., et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE, 7, 2012 e33536.
10. [10] Wijnans, L., Lecomte, C., de Vries, C., et al. The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine 31 (2013), 1246–1254.
11. [11] Partinen, M., Saarenpää-Heikkilä, O., Ilveskoski, I., et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS ONE, 7, 2012 e33723.
12. [12] Dauvilliers, Y., Arnulf, I., Lecendreux, M., et al. Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. Brain 136 (2013), 2486–2496.
13. [13] Partinen, M., Kornum, B.R., Plazzi, G., et al. Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination. Lancet Neurol 13 (2014), 600–613.
14. [14] Liblau, R.S., Vassalli, A., Seifinejad, A., et al. Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy. Lancet Neurol 14 (2015), 318–328.
15. [15] Adams, J.S., Hewison, M., Update in vitamin D. J Clin Endocrinol Metab 95 (2010), 471–478.
16. [16] Rosen, C.J., Adams, J.S., Bikle, D.D., et al. The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. Endocr Rev 33 (2012), 456–492.
17. [17] Eyles, D.W., Smith, S., Kinobe, R., et al. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat 29 (2005), 21–30.
18. [18] Edfeldt, K., Liu, P.T., Chun, R., et al. T-cell cytokines differentially control human monocyte antimicrobial responses by regulating vitamin D metabolism. Proc Natl Acad Sci USA 107 (2010), 22593–22598.
19. [19] Von Essen, M.R., Kongsbak, M., Schjerling, P., et al. Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nat Immunol 11 (2010), 344–349.
20. [20] Ramagopalan, S.V., Maugeri, N.J., Handunnetthi, L., et al. Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet, 5, 2009 e1000369.
21. [21] Ebers, G.C., Environmental factors and multiple sclerosis. Lancet Neurol 7 (2008), 268–277.
22. [22] Pierrot-Deseilligny, C., Souberbielle, J.-C., Is hypovitaminosis D one of the environmental risk factors for multiple sclerosis?. Brain 133 (2010), 1869–1888.
23. [23] Degn, M., Kornum, B.R., Type 1 narcolepsy: a CD8(+) T cell-mediated disease?. Ann N Y Acad Sci 1351 (2015), 80–88.
24. [24] Mowry, E.M., Krupp, L.B., Milazzo, M., et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol 67 (2010), 618–624.
25. [25] Mowry, E.M., Waubant, E., McCulloch, C.E., et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol 72 (2012), 234–240.
26. [26] Carlander, B., Puech-Cathala, A.M., Jaussent, I., et al. Low vitamin D in narcolepsy with cataplexy. PLoS ONE, 6, 2011, e20433.
27. [27] Iber, C., Ancoli-Israel, S., Chesson, A., et al. The AASM manual for the scoring of sleep and associated events; rules, terminology and technical specifications. for the; American Academy of Sleep Medicine, 1st ed, 2007, American Academy of Sleep Medicine, Westchester (IL).
28. [28] Littner, M.R., Kushida, C., Wise, M., et al. Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test. Sleep 28 (2005), 113–121.
29. [29] AASM: American Academy of Sleep Medicine, ICSD-3: International Classification of Sleep Disorders. 3rd ed, 2014, American Academy of Sleep Medicine, Westchester (IL).
30. [30] National Heart, Lung and Blood Institute, Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. 1998, National Heart, Lung, and Blood Institute, Bethesda (MD).
31. [31] Souberbielle, J.-C., Body, J.-J., Lappe, J.M., et al. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: recommendations for clinical practice. Autoimmun Rev 9 (2010), 709–715.
32. [32] Looker, A.C., Pfeiffer, C.M., Lacher, D.A., et al. Serum 25-hydroxyvitamin D status of the US population: 1988–1994 compared with 2000–2004. Am J Clin Nutr 88 (2008), 1519–1527.
33. [33] Yetley, E.A., Assessing the vitamin D status of the US population. Am J Clin Nutr 88 (2008), 558S–564S.
34. [34] Mora, J.R., Iwata, M., von Andrian, U.H., Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol 8 (2008), 685–698.
35. [35] Liu, P.T., Stenger, S., Li, H., et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311 (2006), 1770–1773.
36. [36] Peelen, E., Knippenberg, S., Muris, A.H., et al. Effects of vitamin D on the peripheral adaptive immune system: a review. Autoimmun Rev 10 (2011), 733–743.
37. [37] Lecendreux, M., Libri, V., Jaussent, I., et al. Impact of cytokine in type 1 narcolepsy: role of pandemic H1N1 vaccination ?. J Autoimmun 60 (2015), 20–31.
38. [38] Ouyang, W., Kolls, J.K., Zheng, Y., The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 28 (2008), 454–467.
39. [39] Dauvilliers, Y., Bauer, J., Rigau, V., et al. Hypothalamic immunopathology in anti-Ma-associated diencephalitis with narcolepsy-cataplexy. JAMA Neurol 70 (2013), 1305–1310.